Advertisment
Merck to showcase new cardiovascular research at ACC 25, including phase 3 ZENITH trial results
Merck known as MSD outside of the United States and Canada, announced that new clinical and outcomes research data will be presented at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.25) in Chicago from March 29-31. Data being shared at the meeting highlights how Merck is advancing research focused on improving outcomes for even more patients living with cardiovascular disease, through the evaluation of approved treatments, as well as data supporting opportunities for improved disease management in a real-world setting.
Merck will present results from the Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) when added to background therapy in adults with pulmonary arterial hypertension (PAH, Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality. These results will be shared as an oral presentation in a late-breaking session on Monday, March 31 during the Clinical and Investigative Horizons I session from 10:00-11:00 a.m. ET/9:00-10:00 a.m. CT (LBA402-16).
“Merck has a long legacy of making an impact in cardiovascular disease, and since we introduced our first therapy more than 60 years ago, we have remained committed to advancing innovative research to better understand and help improve the lives of patients with cardiovascular disease,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. “We are particularly thrilled to share research from the Phase 3 ZENITH trial evaluating WINREVAIR in PAH as a late-breaking presentation. ZENITH is the first study in PAH in which the interim analysis led to an early conclusion due to overwhelming efficacy and adds to the growing body of data evaluating WINREVAIR in a broad spectrum of patients with PAH.”
Four outcomes research presentations focused on cholesterol management from Merck will also be shared during the meeting. These include two presentations evaluating real-world data: the first highlights healthcare utilization and costs among patients treated for dyslipidemia in a U.S. integrated delivery system and the second provides insights into low-density lipoprotein (LDL-C) measurement patterns. Two additional presentations include a model to estimate the impact of treatment patterns for adults on lipid lowering therapy (LLT), as well as a systematic literature review and meta-analysis of residual atherosclerotic cardiovascular disease (ASCVD) risk among those treated with statin therapy.
“Our commitment to improving the lives of patients includes driving analyses of observational data to provide valuable insights into the barriers to achieving LDL-C goals in order to manage atherosclerotic cardiovascular disease,” said Dr. Bjorn Oddens, senior vice president and head of value and implementation, Merck Research Laboratories. “Low-density lipoprotein cholesterol is an established and modifiable risk factor for the development of atherosclerotic cardiovascular disease, a disease which accounts for 85 percent of cardiovascular deaths, but nearly two-thirds of individuals do not reach their LDL-C goals. Research presented at ACC aims to provide the cardiovascular community with insights into existing gaps in management, the impact on patient outcomes and healthcare systems and opportunities for improvement, with the ultimate goal of helping more patients better manage their LDL-C.”
Key data from Merck to be presented at ACC.25:
- First presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR when added to background therapy in patients with PAH FC III or IV at high risk of mortality (Abstract #LBA402-16; Clinical and Investigative Horizons I);
- A systematic review and meta-analysis evaluating the residual ASCVD risk in statin users in the real-world setting (Abstract #1062-36; Cardiovascular Disease Prevention 03);
- Real-world data evaluating the frequency of LDL-C measurement and its association with patient characteristics among adults prescribed LLT in the U.S. (Abstract #1062-19; Cardiovascular Disease Prevention 03);
- Presentation of a model to estimate the benefits of non-statin LLT use in terms of clinical (LDL-C and ASCVD event reduction) and economic (cost reduction) impact on the U.S. health system (Abstract #977-03; Costs of Cardiovascular Preventive Care: Implications Across Stakeholders);
- Poster presentation estimating the association between healthcare resource use and treatment patterns among adults on LLT across various levels of risk in a large U.S. health system (Abstract #977-15; Costs of Cardiovascular Preventive Care: Implications Across Stakeholders).
